title: Prognostic analysis for survival in adult solid organ transplant recipients with post-transplantation lymphoproliferative disorders.
abstract: OBJECTIVE
  The objective of this study was to determine prognostic factors for overall survival in patients with post-transplantation lymphoproliferative disorders (PTLDs).
  
  
  METHODS
  This study focused on the 107 adult solid organ transplantation patients who were diagnosed with PTLDs at Mayo Clinic (Rochester, MN) between December 1970 and May 2003.
  
  
  RESULTS
  The median age at the time of diagnosis was 48 years (range, 15 to 75 years). Extranodal disease including grafted organ involvement was present in 85 patients (80%). The graft organ was involved in 30 patients (28%). At the time of these analyses, 62 patients (58%) had died. The median survival for the entire cohort was 31.5 months (95% CI, 10.7 to 72.5 months). The median follow-up of living patients was 51.8 months (range, 5.6 to 202.6 months). In univariate analyses for overall survival from the time of PTLD diagnosis, the following poor prognostic factors were identified: poor performance status with Eastern Cooperative Oncology Group levels 3 and 4 (P < .0001), grafted organ involvement (P = .0005), the presence of one or more extranodal sites (P = .005), both nodal and extranodal disease (P = .002), high International Prognostic Index (P = .006), advanced stage (P = .001), and elevated lactate dehydrogenase (P = .03). A final multivariable model for survival was constructed using three factors: poor performance status (3 to 4), monomorphic disease, and graft organ involvement.
  
  
  CONCLUSIONS
  A prognostic model has been developed for PTLD patients using one center's 30 years of experience. We propose additional confirmation and validation of these prognostic factors in larger prospective studies.
authors.affiliation: Division of Hematology, Department of Internal Medicine, Mayo Clinic and Mayo Foundation, 200 First St, SW, Rochester, MN 55905, USA.
authors.forename: Irene M
authors.initials: IM
authors.lastname: Ghobrial
authors.forename: Thomas M
authors.initials: TM
authors.lastname: Habermann
authors.forename: Matthew J
authors.initials: MJ
authors.lastname: Maurer
authors.forename: Susan M
authors.initials: SM
authors.lastname: Geyer
authors.forename: Kay M
authors.initials: KM
authors.lastname: Ristow
authors.forename: Timothy S
authors.initials: TS
authors.lastname: Larson
authors.forename: Randall C
authors.initials: RC
authors.lastname: Walker
authors.forename: Stephen M
authors.initials: SM
authors.lastname: Ansell
authors.forename: William R
authors.initials: WR
authors.lastname: Macon
authors.forename: Gregory G
authors.initials: GG
authors.lastname: Gores
authors.forename: Mark D
authors.initials: MD
authors.lastname: Stegall
authors.forename: Christopher G
authors.initials: CG
authors.lastname: McGregor
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D002648:Child; D005260:Female; D006801:Humans; D008232:Lymphoproliferative Disorders / Q000175:diagnosis* / Q000209:etiology* / Q000628:therapy; D008297:Male; D008875:Middle Aged; D016377:Organ Transplantation / Q000009:adverse effects*; D011183:Postoperative Complications / Q000453:epidemiology / Q000209:etiology* / Q000628:therapy; D011379:Prognosis; D012074:Remission Induction; D012189:Retrospective Studies; D012307:Risk Factors; D015996:Survival Rate; D016896:Treatment Outcome